Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab
TILD-19-12
Phase 3 small_molecule active
Quick answer
Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab for Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active